Background: Mast cells are immunocompetent cells that are found in almost all tissues and function as sentinels of immune responses. Recently, it has been shown that mast cells play significant roles in innate immune responses. However, it is still largely unknown whether signal transducers and activators of transcription 4 (STAT4), one of the STAT proteins under type I IFN signaling, is involved in type I IFN-mediated gene expression in mast cells. Methods: We investigated the role of STAT4 in IFN-β-induced gene expression in mast cells by using STAT4-deficient (STAT4–/–) bone marrow-derived mast cells (BMMCs). Results: STAT4 was expressed in BMMCs and activated in response to IFN-β but not to IL-12 or IL-23. The development of BMMCs as well as IgE-induced degranulation of BMMCs was normal in STAT4–/– mice. On the other hand, while IFN-β-induced mRNA expression of interferon-induced protein with tetratricopeptide repeats 1 (IFIT-1), protein kinase interferon-inducible double stranded RNA dependent (PKR), and myxovirus resistance 1 (Mx1) was similar between STAT4–/– BMMCs and wild-type (WT) BMMCs, IFN-β-induced MCP-1 mRNA expression was severely diminished in STAT4–/– BMMCs as compared with WT BMMCs. Conclusions: STAT4 plays an essential role in IFN-β-induced MCP-1 mRNA expression in mast cells.

1.
Galli SJ, Hammel I: Mast cell and basophil development. Curr Opin Hematol 1994;1:33–39.
2.
Metcalfe DD, Baram D, Mekori YA: Mast cells. Physiol Rev 1997;77:1033–1079.
3.
Echtenacher B, Mannel DN, Hultner L: Critical protective role of mast cells in a model of acute septic peritonitis. Nature 1996;381:75–77.
4.
Malaviya R, Ikeda T, Ross E, Abraham SN: Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-α. Nature 1996;381:77–80.
5.
Malaviya R, Gao Z, Thankavel K, Merwe PA, Abraham SN: The mast cell tumor necrosis factor α response to FimH-expressing Escherichia coli is mediated by the glycosylphosphatidylinositol-anchored molecule CD48. Proc Natl Acad Sci USA 1999;96:8110–8115.
6.
McCurdy JD, Lin TJ, Marshall JS: Toll-like receptor 4-mediated activation of murine mast cells. J Leukoc Biol 2001;70:977–984.
7.
Pestka S, Langer JA, Zoon KC, Samuel CE: Interferons and their actions. Annu Rev Biochem 1987;56:727–777.
8.
Leonard WJ, O’Shea JJ: JAKs and STATs: biological implications. Annu Rev Immunol 1998;16:293–322.
9.
Darnell JE Jr, Kerr IM, Stark GR: JAK-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264:1415–1421.
10.
Ihle JN, Nosaka T, Thierfelder W, Quelle FW, Shimoda K: JAKs and STATs in cytokine signaling. Stem Cells 1997;15:105–111.
11.
Ikeda K, Nakajima H, Suzuki K, Watanabe N, Kagami SI, Iwamoto I: STAT5a is essential for the proliferation and survival of murine mast cells. Int Arch Allergy Immunol 2005;137:s45–s50.
12.
Suzuki K, Nakajima H, Kagami SI, Suto A, Ikeda K, Hirose K, Hiwasa T, Takeda K, Saito Y, Akira S, Iwamoto I: Proteolytic processing of STAT6 signaling in mast cells as a negative regulatory mechanism. J Exp Med 2002;196:27–38.
13.
Suzuki K, Nakajima H, Ikeda K, Maezawa Y, Suto A, Takatori H, Saito Y, Iwamoto I: IL-4-STAT6 signaling induces tristetraprolin expression and inhibits TNF-α production in mast cells. J Exp Med 2003;198:1717–1727.
14.
Kaplan MH, Sum YL, Hoey T, Grusby MJ: Impaired IL-12 responses and enhanced development of Th2 cells in STAT4-deficient mice. Nature 1996;382:174–177.
15.
Suzuki K, Nakajima H, Watanabe N, Kagami S, Suto A, Saito Y, Saito T, Iwamoto I: Role of common cytokine receptor γ chain (γc)- and Jak3-dependent signaling in the proliferation and survival of murine mast cells. Blood 2000;96:2172–2180.
16.
Watford WT, Hissong BD, Bream JH, Kanno Y, Muul L, O’Shea JJ: Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev 2004;202:139–156.
17.
Berenson LS, Gavrieli M, Farrar JD, Murphy TL, Murphy KM: Distinct characteristics of murine STAT4 activation in response to IL-12 and IFN-α. J Immunol 2006;177:5195–5203.
18.
Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M: Mast cells as ‘tunable’ effector and immunoregulatory cells: recent advances. Annu Rev Immunol 2005;23:749–786.
19.
Galli SJ, Nakase S, Tsai M: Mast cells in the development of adaptive immune responses. Nat Immunol 2005;6:135–142.
20.
Sadler AJ, Williams BR: Interferon-inducible antiviral effectors. Nat Rev Immunol 2008;8:559–568.
21.
Randall RE, Goodbourn S: Interferons and viruses: an interplay between induction, signaling, antiviral responses and virus countermeasures. J Gen Virol 2008;89:1–47.
22.
O’Shea JJ, Murray PJ: Cytokine signaling modules in inflammatory responses. Immunity 2008;28:477–487.
23.
Desshmane SL, Kremlev S, Amini S, Sawaya BE: Monocyte chemoattractant protein 1 (MCP-1): an overview. J Interferon Cytokine Res 2009;29:313–326.
24.
Li H, Gade P, Xiao W, Kalvakolanu DV: The interferon signaling network and transcription factor C/EBP-β. Cell Mol Immunol 2007;4:407–418.
25.
Wesoly J, Szweykowska-Kulinska Z, Bluyssen HA: STAT activation and differential complex formation dictate selectivity of interferon responses. Acta Biochim Pol 2007;54:27–38.
26.
Fitzgerland-Bocarsly P, Dai J, Singh S: Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. Cytokine Growth Factor Rev 2008;19:3–19.
27.
Hokeness KL, Kuziel WA, Biron CA, Salazar-Mather TP: Monocyte chemoattractant protein-1 and CCR2 interactions are required for IFNα/β-induced inflammatory responses and antiviral defense in liver. J Immunol 2005;174:1549–1556.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.